Synthesis and cytotoxic activity of indolyl thiazoles

Anti-Cancer Drugs

Volumn 8, Issue 5, 1997, Pages 489-499

  Moody, Christopher J ^a,c   Roffey, Jonathan R A ^a   Stephens, Miriam A ^b   Stratford, Ian J ^b,d  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cytotoxicity; Indole; Thiazole

Indexed keywords

2 (2 BENZOTHIAZOLYL) 1 METHYLINDOLE; 3 (4 THIAZOLYL)INDOLE; ANTINEOPLASTIC AGENT; CAMALEXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOPATHOGENIC EFFECT; DRUG CONFORMATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0030757256     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199706000-00012     Document Type: Article

References (30)

1. Kane SA, Sasaki H, Hecht SM. Guanosine-specific DNA damage by a Co(II)-bithiazole complex. J Am Chem Soc 1995; 117: 9107-18.
2. Kumar Y, Green R, Wise DS, et al. Synthesis of 2,4-disubstituted thiazoles and selenazoles as potential antifilarial and antitumor agents. 2-Arylamido and 2-alkylamido derivatives of 2-amino-4-(isothiocyanatomethyl)thiazole and 2-amino-4-(isothiocyanatomethyl)-selenazole. J Med Chem 1993; 36: 3849-52.
3. Stratmann K, Belli J, Jensen CM, et al. Aulosirazole, a novel solid tumor selective cytotoxin from the blue green alga Aulosira fertilissima. J Org Chem 1994; 59: 6279-81.
4. Ojika M, Nemoto T, Nakamura M, et al. Dolastatin E, a new cyclic hexapeptide isolated from the sea hare Dolabella auricularia. Tetrahedron Lett 1995; 36: 5057-8.
5. Jones GB, Moody CJ. Structurally modified antitumour agents. Part 2. Total synthesis of a cyclopropamitosene. J Chem Soc, Perkin Trans 1 1989; 2455-62.
6. Cotterill AS, Hartopp P, Jones GB, et al. Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis of 7-methoxycyclopropamitosene and related indolequinones. Tetrahedron 1994; 50: 7657-74.
7. Oka H, Yoshinari T, Murai T, et al. A new topoisomerase-II inhibitor, BE-10988, produced by a Streptomycete. I. Taxonomy, fermentation, isolated and characterization. J Antibiot 1991; 44: 486-91.
8. Suda H, Matsunaga K, Yamamura S, et al. Structure of a new topoisomerase II inhibitor BE 10988. Tetrahedron Lett 1991; 32: 2791-2.
9. Moody CJ, Swann E. Synthesis of the topoisomerase II inhibitor BE 10988. Tetrahedron Lett 1993; 34: 1987-8.
10. Moody CJ, Swann E. Synthesis of the naturally occurring indolequinone BE 10988, an inhibitor of topoisomerase II. J Chem Soc, Perkin Trans 1 1993; 2561-5.
11. Suda H, Ohkubo M, Matsunaga K, et al. Total synthesis of a new topoisomerase inhibitor BE 10988. Tetrahedron Lett 1993; 34: 3797-8.
12. Moody CJ, Swann E, Houlbrook S, et al. Synthesis and biological activity of thiazolyl indolequinones, analogues of the natural product BE 10988. J Med Chem 1995; 38: 1039-43.
13. Stevens MFG, Shi D-F, Castro A. Antitumour benzothiazoles. Part 2. Formation of 2,2′-diaminobiphenyls from the decomposition of 2-(4-azidobiphenyl)benzazoles in trifluoromethanesulfonic acid. J Chem Soc, Perkin Trans 1 1996; 83-93.
14. Shi DF, Bradshaw TD, Wrigley S, et al. Antitumour benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast-cancer cell-lines in-vitro and in-vivo. J Med Chem 1996; 39: 3375-84.
15. Wheelhouse RT, Shi DF, Wilman DEV, et al. Anti-tumour benzothiazoles. 4. An NMR-study of the sites of protonation of 2-(4-aminophenyl)benzothiazoles. J Chem Soc, Perkin Trans 2 1996; 1271-4.
16. Ayer WA, Craw PA, Ma Y, et al. Synthesis of camalexin and related phytoalexins. Tetrahedron 1992; 48: 2919-24.
17. Bergman J, Bäckvall J-E, Lindström J-O. Synthesis and reactions of some 3-(2-haloacyl)indoles. Tetrahedron 1973; 29: 971-6.
18. Bergman J, Bäckvall JE. Base induced rearrangements of 3-(α-haloacyl)indoles. Tetrahedron 1975; 31: 2063-73.
19. Harington CR, Moggridge RCG. α-Amino-β-(4-methylthiazol-5)-propionic acid, a possible precursor of aneurin. J Chem Soc 1939; 443-6.
20. Arya VP, David J, Grewal RS, et al. Synthesis and CNS depressant activity of some 2,3-disubstituted indoles. Ind J Chem 1977; 15: 473-7.
21. Smith K, Houlbrook S, Greenall M, et al. Topoisome-rase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8: 933-8.
22. Houlbrook S, Carmichael J, Davies S, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995; 72: 1454-61.
23. Carmichael J, Degraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitizing testing. Cancer Res 1987; 47: 936-42.
24. Stratford IJ, Stephens MA. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 1989; 16: 973-6.
25. Kirk J, Houlbrook S, Stuart NSA, et al. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 1993; 67: 1189-95.
26. Heaney H, Ley SV. N-Alkylation of indole and pyrroles in dimethyl sulphoxide. J Chem Soc, Perkin Trans 1 1973; 499-500.
27. Lipton MF, Basha A, Weinreb SM. Conversion of esters to amides with dimethylaluminum amides. Org Synth 1988; 6: 492-5.
28. Hudkins RL. Synthesis of 1H-indolyl-2-benzimidazoles and 1H-indolyl-2-benzothiazoles. Heterocycles 1995; 41: 1045-9.
29. Cotterill AS, Moody CJ, Mortimer RJ, et al. Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry and biological activity of 7-substituted cyclopropamitosenes and related indole-quinones. J Med Chem 1994; 37: 3834-43.
30. Houlbrook S, Kirk J, Stuart NSA, et al. Human tumor cell lines: a valuable method for the evaluation of new drugs and for the evaluation of mechanisms underlying cytotoxic drug resistance. Oncol (Life Sci Adv) 1994; 13: 69-76.